Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00052845 · ClinicalTrials.gov registry record · Phase 2
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase 2 study of Prostate Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 20
- Study locations
NCT00052845: Completed Phase 2 study of Prostate Cancer, sponsored by Alliance for Clinical Trials in Oncology.
NCT00052845 is a Phase 2 study of Prostate Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 80 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00052845, a Phase 2 study of Prostate Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Estramustine may fight prostate cancer by reducing the production of androgens. Exisulind may stop the growth of prostate cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining these therapies may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining estramustine with exisulind and docetaxel in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.
Conditions Studied
Interventions
- DRUG docetaxel
- DRUG exisulind
- DRUG estramustine phosphate sodium
Study Locations (20)
California
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center - Los Angeles
- Veterans Affairs Medical Center - San Diego - San Diego
- UCSF Comprehensive Cancer Center - San Francisco
- Veterans Affairs Medical Center - San Francisco - San Francisco
Florida
- Broward General Medical Center - Fort Lauderdale
- Memorial Regional Hospital Comprehensive Cancer Center - Hollywood
- CCOP - Mount Sinai Medical Center - Miami Beach
- Florida Hospital Cancer Institute - Orlando
- Palm Beach Cancer Institute - West Palm Beach
Illinois
- MBCCOP - University of Illinois at Chicago - Chicago
- Veterans Affairs Medical Center - Chicago (Westside Hospital) - Chicago
- University of Chicago Cancer Research Center - Chicago
- Louis A. Weiss Memorial Hospital - Chicago
- West Suburban Center for Cancer Care - River Forest
District of Columbia
- Lombardi Cancer Center of Georgetown University Medical Center - Washington D.C.
- Walter Reed Army Medical Center - Washington D.C.
- Veterans Affairs Medical Center - Washington, DC - Washington D.C.
Alabama
- Northeast Alabama Regional Medical Center - Anniston
Delaware
- CCOP - Christiana Care Health Services - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2002-11 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
What the finished NCT00052845 record still lists
NCT00052845 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which docetaxel is the first listed.
NCT00052845 names 20 study sites across 6 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00052845 about?
NCT00052845 is a clinical study titled "Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy". RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Estramustine may fight prostate cancer by reducing the production of androgens. Exisulind may stop the growth of prostate cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor ce...
What is the current status of trial NCT00052845?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2002-11. Estimated completion is 2009-04.
What conditions does trial NCT00052845 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00052845?
The interventions under investigation include: docetaxel (DRUG), exisulind (DRUG), estramustine phosphate sodium (DRUG).
Who is sponsoring clinical trial NCT00052845?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00052845 being conducted?
This trial has 20 study locations across Alabama, California, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00052845's enrollment target sits among peer trials
80 370th of 735 higher than 355 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia